Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 28853

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Diagnostic
  • Disease
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28853

License Grant
The Israeli Licensee entered into a licensing Agreement with the Israeli Licensor, the technology transfer company of the University, to research, develop, and commercialize hCDR1.
“Licence” shall mean an exclusive, worldwide, sublicenseable licence to use the Licensed Information and under the Patents, for the research, development, production, marketing and sale of Products, subject to the provisions of clause 4 below and the other terms and conditions of this Agreement.
License Property
hCDR1, is a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus, or SLE, the most prominent type of Lupus, among other indications. hCDR1, is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process.

U.S.A* 08/913,994 – 6,613,536

1.
A method to dissolve the peptide (hCDR1) in PBS for the tolerogenic administration.

2.
Mode of injection of hCDR1 for the prevention of an autoimmune response.

3.
Characterization of the isotypes of the antibodies produced following a chronic treatment with hCDR1.

4.
Binding of hCDR1 to MHC class II on APC in comparison with control peptides.

5.
Determination of complement C3 levels in sera of mouse models and effects of treatment with hCDR1.

6.
Assays for the evaluation of the effects of treatment with hCDR1 in the presence of immunosuppressive drugs (such as Methotrexate, Mofetil Mycophenolate, Immuran) used for the treatment of lupus (especially lupus nephritis).

7.
Methods to assess the effects of treatment with hCDR1 on CNS lupus (pathology and behavior dysfunction) in spontaneous and induced experimental SLE.

8.
Determination of anti-NMDA specific antibodies in sera of mice with induced lupus and the effects of hCDR1 on the latter.

9.
Induction of neurogenesis and expression of BDNF in brains of SLE afflicted mice following treatment with hCDR1.

10.
Methods to determine B cell dysfunction and the effect of hCDR1 on the latter especially in the target organs of lupus, namely, brain and kidney.

11.
Evaluation of hCDR1 activity using a short term in vitro assay. This method was used in one of our publications and is written in the Methods section. However, because this technology can be used in the future to determine whether a patient might be a responder to the treatment of hCDR1 (which is not mentioned in the publication) we think that it might be the most important know how of the whole list.

Field of Use
Lupus is a debilitating disease affecting approximately five million people worldwide. hCDR1, is a peptide and acts as a disease-specific treatment to modify the SLE-related autoimmune process. It does so by specific upstream immunomodulation through the generation of regulatory T cells, reducing inflammation and resuming immune balance.

IPSCIO Record ID: 281494

License Grant
The Company amended its agreements with Licensee  relating to the launch of monitoring product using CB-CAPs technology.
License Property
The proprietary CB-CAPs technology determines the blood levels of complement activation proteins permanently deposited on hematopoeitic cells. The determination of complement proteins in a patient’s blood is a mainstay in clinical laboratory science, and state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of complement activation.
Field of Use
CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE.

IPSCIO Record ID: 28107

License Grant
The Licensor has licensed the exclusive worldwide rights for the treatment of non-cancer indications to one of our most advanced therapeutic compounds, epratuzumab to the Belgium Licensee. The Licensee is granted the right to sublicense epratuzumab, subject to obtaining the Licensor's prior consent, to a third party for the United States and certain other territories, according to the Amendment Agreement.
License Property
Epratuzumab is a humanized monoclonal antibody targeting CD22 receptors on B lymphocytes. It is being evaluated for the treatment of non-Hodgkin’s lymphoma, and for autoimmune diseases such as systemic lupus erythematosus (SLE). The U.S. Food and Drug Administration has granted Epratuzumab Fast Track Product designation for the treatment of patients with lupus.
Field of Use
Epratuzumab has been licensed for all autoimmune disease indications worldwide to the biopharmaceutical manufacturing company.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.